ANVS Annovis Bio, Inc.
USHealthcareAs of 2026-07-09 11:02
Why ANVS matters now
Annovis Bio, Inc. (ANVS) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.96 with -1.76% on the session and $38.5M in market capitalization; recent performance reads 1-month -9.79% and YTD -49.42%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-17.6M, and EPS of $-0.63. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -77.1%.
The latest indexable market news headline is "Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $26.00; recent insider activity includes Hoffman Michael B filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
15.59
P/S
0.00
EV/EBITDA
-0.49
DCF Value
$0.84
FCF Yield
-77.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-318.1%
ROA
-251.9%
ROIC
-1199.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-17.6M | $-0.63 |
| Q4 2025 | $0.00 | $-9.8M | $-0.40 |
| FY 2025 | $0.00 | $-28.9M | $-1.40 |
| Q3 2025 | $0.00 | $-7.3M | $-0.37 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$25.67
Target (Median)
$26.00
Target Range
$21.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.19
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.